Phase Ia, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic, or biliary cancers.

Andrew H. Ko,Andrew L. Coveler,Benjamin L. Schlechter,Tanios Bekaii-Saab,Brian M. Wolpin,Jeffrey W. Clark,Yi Lin Cheng,Ting Ying Cheng,Peter Langecker,Shih-Yao Lin

Phase Ia, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic, or biliary cancers.

2020

Andrew H. Ko
Andrew L. Coveler
Benjamin L. Schlechter
Tanios Bekaii-Saab
Brian M. Wolpin
Jeffrey W. Clark
Yi Lin Cheng
Ting Ying Cheng
Peter Langecker
Shih-Yao Lin

713Background: AbGn-107 is an ADC directed against AG-7 antigen, a Lewis A-like glycol-epitope expressed in 24-61% of gastric (G), colorectal (CRC), pancreatic (PDA), and biliary (BIL) cancers. Bas...

Keywords:

Biliary cancers
Cancer research
Medicine
Antibody-drug conjugate
Pathology
Human study
in patient
Antigen
first in human

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations